LDS/Medical Tests/Everolimus, Blood

Everolimus, Blood

Everolimus is a potent immunosuppressive agent utilized primarily to prevent rejection following kidney transplantation. Kidney transplantation is the definitive therapy for End-Stage Renal Disease (ESRD). However, due to inherent immunological incompatibility between donor tissues and recipients, immunosuppressive agents are necessary to prevent acute and chronic graft rejection.

Everolimus specifically inhibits the mammalian target of rapamycin (mTOR) pathway, a critical cellular signaling pathway regulating cell growth, proliferation, differentiation, survival, and metabolism. In immune cells, mTOR inhibition notably suppresses T-cell proliferation, B-cell activation, cytokine release, and antibody production, thereby reducing immune-mediated graft injury and rejection.

Although effective in preventing graft rejection, Everolimus can cause dose-dependent toxicities affecting normal cells. Common adverse effects include stomatitis, leukopenia, anorexia, anemia and fatigue. Additional reported adverse effects encompass hyperlipidemia, thrombocytopenia, impaired wound healing, and nephrotoxicity. Monitoring therapeutic blood levels of Everolimus is critical to achieving the optimal immunosuppressive balance, minimizing adverse effects, and maintaining long-term graft survival.

  • Monitoring therapeutic levels of Everolimus for kidney transplant recipients
  • Preventing Everolimus-associated toxicity through appropriate dose adjustment
  • Optimizing immunosuppressive therapy to enhance graft survival.

Elevated Everolimus Levels (>8 ng/mL):

  • Increased risk of adverse reactions and toxicities; dose reduction is typically indicated.

Reduced Everolimus Levels (<3 ng/mL):

  • nadequate immunosuppression, potential graft rejection risk; dose escalation recommended.

Important Clinical Note:
Interpretation should always incorporate clinical context, concomitant medications, graft function indicators, and laboratory parameters.

3-8 ng/mL

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 28 days
Albumin-to-Creatinine Ratio (ACR), Comprehensive Urinalysis including Microalbumin, Complete Blood Count (CBC) with Differential, Kidney Biopsy (if clinically indicated), HLA Class I and II Genotyping, Prospera™ or Tuteva™ Post-Transplant Rejection Assessment tests, Therapeutic monitoring of other immunosuppressive agents (e.g., Tacrolimus, Sirolimus, Cyclosporine).
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login